Zolpidem Tartrate

Allschwil, Switzerland – September 1, 2025Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global scientific congress bringing the best of sleep medicine and research, in Singapore from September 5-10, 2025. Idorsia’s scientific poster presentations at World Sleep 2025: Real-world data assessment of abuse potential of insomnia therapiesA study to examine the real-world abuse potential of approved and off-label medications used for the treatment of insomnia, using data from the FDA Adverse Event Reporting System (FAERS) database. Real-world data on the abuse potential of medications for the treatment of insomnia. P. Saskin, W.V. McCall, D. Neubauer, A. Crucitti, P.P. Luyet, R. Jaziri, C. Vaillant. Abstract available online Efficacy of daridorexant throughout the night Effect of daridorexant on wakefulness throughout the night: Post-hoc analysis of a randomised, double-blind, active reference (zolpidem) study in patients with insomnia disorder. B. Steiniger-Brach, O. Briasoulis, A. Olivieri, S. Pain, L. Palagini, D. Kunz, P.-A. Geoffroy. Abstract available online Effect of daridorexant on wakefulness throughout the night and morning sleepiness in patients with insomnia disorder. Y. Dauvilliers, G. Zammit, P.-P. Luyet, G. Braunstein, O. Briasoulis, A. Olivieri. Abstract available online Impact of daridorexant in patients with insomnia and additional health conditions Efficacy and safety of daridorexant in women with insomnia disorder during menopausal transition: a subgroup analysis. O. Briasoulis, Z. Schaedel, C. Bassetti, S.M. Bertisch, P. Cassel, S. Palacios, C. Palmay, R. Silvestri, P. Stute, F. Trémollieres, T. Bakker, S. Pain. Abstract available online Efficacy and safety of daridorexant in patients with chronic insomnia disorder and comorbid nocturia. K. Lederer, S. Schoffner, J.-E. Batista Miranda, R. Rowles, A. Olivieri, M. Meinel. Abstract available online Characterization of patients with insomnia disorderThe largest clinical characterization of patients with insomnia disorder to date. Drawing on data from more than 5000 patients screened in the Phase 3 daridorexant program, these analyses provide important insights into the significant and wide-ranging impact of insomnia disorder on objective and subjective nighttime symptoms and daytime functioning. Subgroup analyses by sex and age provide important insights on how insomnia disorder may affect different patient populations. The impact of insomnia disorder on the night and the day: analysis of polysomnography and subjective parameters from a large clinical trial database. M. Fernandes, A. Olivieri, O. Briasoulis, J. Laurent, C. Liguori. Abstract available online The impact of insomnia disorder on the night and the day in older and younger adults. M. Fernandes, A. Olivieri, O. Briasoulis, J. Laurent, C. Liguori. Abstract available online The impact of insomnia disorder on the night and the day in males and females. M. Fernandes, A. Olivieri, O. Briasoulis, J. Laurent, C. Liguori. Abstract available online Educational symposiumOn Tuesday, September 9, from 12:45 to14:15, Idorsia will host an educational symposium featuring experts David Neubauer (US), Lu Lin (China), Atul Khullar (Canada), Laura Palagini (Italy), and Claudio Liguori (Italy). The symposium will explore the link between insomnia and neurological or psychiatric comorbidities, focusing on the role of orexin. New clinical and real-world data on daridorexant will be presented, alongside practical strategies for managing insomnia in patients with comorbidities through case discussions. The event will conclude with a Q&A and panel discussion to foster expert–attendee dialogue. About World Sleep 2025World Sleep 2025 will be the 18th World Sleep Congress. This congress facilitates an international discussion forum and collaboration among sleep societies and sleep professionals. Sleep clinicians, technologists, trainees, educators, and scientists from around the world will meet to advance knowledge on sleep science, sleep in public health, sleep health, and sleep-wake disorders, their diagnosis and treatments. World Sleep Society seeks to maximize learning both from formal presentations by the leading experts in their fields and from informal discussion groups emphasizing opportunities for networking and member participation. Notes to the editor About IdorsiaThe purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

New Delhi: In one of the largest crackdowns on the illegal pharmaceutical trade , the Narcotics Control Bureau (NCB) has dismantled an international drug trafficking syndicate operating across four continents, using encrypted digital platforms, cryptocurrency, and anonymous shipping networks, an official statement said. The breakthrough began with the interception of a vehicle near Bengali Market in Delhi on May 25, 2025, ultimately uncovering a vast transnational operation with links to India, the US, Australia, and Europe. The investigation was launched after the NCB HQ Operations Unit intercepted a car near Mandi House, Delhi, based on a tip-off. The vehicle's two occupants, B. Pharma graduates from a reputed Noida-based private university, were found in possession of 3.7 kg of Tramadol tablets--a controlled medication often misused as a narcotic. Their confession exposed a deeper network that involved an online vendor profile on a major Indian B2B platform, used to ship pharmaceutical pills to clients in the United States, Europe, and Australia. Subsequent leads led NCB to a stockist in Roorkee and an associate in Delhi's Mayur Vihar. Further investigation uncovered a key contact in Udupi, Karnataka, who managed bulk orders for exports. Analysis of seized data from Udupi revealed 50 international consignments 29 within the US, 18 within Australia, and one each to Estonia, Spain, and Switzerland. This intelligence was shared with international counterparts and the International Criminal Police Organisation (Interpol). Acting on this information, the United States Drug Enforcement Administration (DEA) arrested a key operative named Joel Hall, a re-shipper based in Alabama. Authorities seized over 17,000 tablets of controlled medicines from his possession. Multiple crypto wallets and active parcels were recovered, confirming the network's reliance on digital currency and encrypted communications. DEA also intercepted five parcels carrying around 700 grams of Zolpidem, a sedative commonly abused for recreational use. Meanwhile, a clandestine pill-manufacturing facility linked to the network was busted in Australia by local law enforcement. The factory was found producing tablets for export as part of the syndicate's supply chain. Investigations in other countries are ongoing. NCB's probe uncovered a multilayered structure with two distinct modules, orders and supply, managed by handlers using encrypted messaging platforms like Telegram and payment systems involving cryptocurrency, PayPal, and Western Union. The syndicate operated a call centre in Udupi, employing approximately 10 staff members, some of whom were reportedly unaware of the criminal operation. Orders placed via the B2B platform were routed through this call centre. Advance payments were made in cryptocurrency, then circulated through supply chain operators who retained a commission before the payments were disbursed to re-shippers in various countries. According to the NCB, the mastermind who orchestrated the network's logistics and finances from the UAE has been identified, and efforts are ongoing to apprehend him with the assistance of Emirati authorities. Two more Indian nationals were arrested in Jaipur and Delhi in connection with the logistics and supply-side operations. So far, a total of eight individuals have been arrested. In a strategic move to expand operations, repeat customers were converted into stockists or re-shippers, allowing the syndicate to grow its footprint organically across borders. Several such individuals have been identified by partner agencies abroad. NCB has also launched financial and cyber investigations to trace cryptocurrency wallets and hawala channels involved in laundering proceeds. Collaborations are underway with private online platforms to shut down illegal pharmacy listings advertising controlled drugs. This case, authorities say, underlines the growing intersection of digital commerce, encrypted technology, and international logistics in facilitating illicit pharmaceutical trade. It also reinforces the importance of international intelligence-sharing and collaborative enforcement actions.